These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26118565)

  • 1. Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.
    Baum N; Levy J
    Postgrad Med; 2015 Aug; 127(6):654-9. PubMed ID: 26118565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
    Tzou K; Tan WW; Buskirk S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rising prostate specific antigen after radical prostatectomy: a case based review.
    Nasr R; Goldenberg SL
    Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for a rising PSA after radical prostatectomy.
    Carthon BC; Marcus DM; Herrel LA; Jani AB; Rossi PJ; Canter DJ
    Can J Urol; 2013 Jun; 20(3):6748-55. PubMed ID: 23783041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen as a marker of disease activity in prostate cancer.
    Partin AW; Hanks GE; Klein EA; Moul JW; Nelson WG; Scher HI
    Oncology (Williston Park); 2002 Sep; 16(9):1218-24; discussion 1224, 1227-8 passim. PubMed ID: 12380948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: a practical approach to current management of recurrent disease.
    Walczak JR; Carducci MA
    Mayo Clin Proc; 2007 Feb; 82(2):243-9. PubMed ID: 17290734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rising PSA in nonmetastatic prostate cancer.
    Moul JW; Bañez LL; Freedland SJ
    Oncology (Williston Park); 2007 Nov; 21(12):1436-45; discussion 1449, 1452, 1454. PubMed ID: 18077992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
    Naito S
    Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen recurrence after definitive therapy.
    Freedland SJ; Moul JW
    J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rising Prostate Specific Antigen following treatment with curative intention].
    Jakobsen H; Pedersen KV
    Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to do for prostate cancer patients with a rising PSA?--A survey of Australian practice.
    Duchesne GM; Millar JL; Moraga V; Rosenthal M; Royce P; Snow R
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):986-91. PubMed ID: 12605977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR; Lapeyrolerie T
    J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.